Efficacy of lamotrigine in disabling myoclonus in a patient with an mtDNA a3243g mutation

Neurology

Volumn 72, Issue 14, 2009, Pages 1279-1280

  Costello, Daniel J ^a   Sims, Katherine B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; MITOCHONDRIAL DNA; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE; VITAMIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DNA DETERMINATION; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; MALE; MUTATIONAL ANALYSIS; MYOCLONUS; PRIORITY JOURNAL; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; ELECTROENCEPHALOGRAPHY; GENETICS; MUTATION; PHYSIOLOGY;

ANTICONVULSANTS; DNA, MITOCHONDRIAL; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; MUTATION; MYOCLONUS; TRIAZINES; VITAMINS; YOUNG ADULT;

EID: 65249087865     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000345663.71421.1d     Document Type: Article

References (3)

1. Canafoglia L, Franceschetti S, Antozzi C, et al. Epileptic phenotypes associated with mitochondrial disorders. Neurology 2001;56:1340-1346.
2. Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005;65: 762-764.
3. Genton P, Gelisse P, Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 2006;47:2083- 2085.